Onc.ai
About Onc.ai
Onc.ai is a privately held digital health company dedicated to improving oncology decision-making through advanced AI-powered imaging biomarkers. Their Onclara™ platform utilizes a comprehensive real-world oncology dataset, including diagnostic imaging, EMRs, and genomics, to train predictive and prognostic AI models. These models are designed to extract and quantify complex imaging features from routine CT scans—such as tumor radiomic signatures, multi-site tumor burden, vascular structure, and body composition—that are often imperceptible to the human eye.
For physicians, Onc.ai’s solutions aim to provide clearer insights into disease progression and therapeutic effectiveness, thereby supporting personalized treatment decisions. Their products, such as Onclara™ Evaluate and Onclara™ IO, are developed to assist in areas like Phase IB/Phase II clinical trial decision-making for pharmaceutical companies and predicting response and outcomes for metastatic lung cancer patients treated with immunotherapy. The company’s Serial CT Response Score (Serial CTRS) AI model has received FDA Breakthrough Device Designation, and their Lung Clinical Management (LCM) product is currently under FDA review, highlighting their commitment to bringing validated AI tools into clinical practice.
Focus Areas
Business Intelligence
| Key Investors | National Cancer Institute, 515 Ventures, Action Potential Venture Capital, Life Extension Ventures, Massachusetts Mutual Life Insurance, Blue Venture Fund, Accomplice, Digitalis Ventures, KdT Ventures |
| Partnerships | Flatiron Health, GSK, Pfizer, Oracle Cloud Infrastructure (OCI), Valohai |
| Technology | Cloud-based analytics interface, deep learning imaging platform, multimodal modeling approach, leverages Valohai MLOps platform on Oracle Cloud Infrastructure (OCI) for GPU workloads across AWS, Azure, and GCP. |
| FDA Clearances | 1 (FDA Breakthrough Device Designation for Serial CTRS AI model) cleared products (estimated) |
What Physicians Need to Know
For physicians, Onc.AI's solutions offer enhanced clarity in oncology decision-making by providing patient-specific prognostic risk assessments and standardized imaging biomarker reports. The Onclarau2122 IO product can help predict response and outcomes for metastatic lung cancer patients undergoing immunotherapy, aiding in personalized treatment strategies. The automated nature of their deep learning pipeline means routine CT scans can be processed without additional input, delivering predictions directly to the oncology EMR or as PDF reports. This allows for more informed discussions with patients about care goals and potential treatment changes, especially for identifying poor prognosis patients who may benefit from altered strategies or increased surveillance.
Onc.AI's platform is designed for effortless integration into existing clinical workflows. It can securely retrieve and process routine clinical CT scans and return predictions as PDF reports or directly into oncology EMR systems. For pharmaceutical partners, Onclarau2122 can be deployed directly in their cloud environments (e.g., Microsoft Azure Foundry) or data can be securely uploaded to Onclarau2122 Studio, with data transfer also supported by leading pharma/oncology CROs.
What the Web Says
Onc.ai is a digital health company focused on improving oncology decision-making through AI-powered predictive and prognostic models. Their Onclarau2122 platform leverages real-world oncology data to enhance clinical trial decision-making and predict treatment response for metastatic lung cancer. The company has received FDA Breakthrough Device Designation for one of its products.
Overall: PositiveStrengths
- Developing innovative AI imaging models for precision oncology.
- Opportunity to make a meaningful impact on cancer treatment.
- Talented, curious, and collaborative team.
- Remote-first company with company-sponsored events.
- Unlimited PTO and solid healthcare benefits (US and Canada).
- Opportunities for continuous learning and professional growth.
Limitations
- Limited public product reviews available on major platforms like G2, Glassdoor, and Capterra.
- Some general skepticism on Reddit regarding the current capabilities of AI in oncology for critical decision-making, with concerns about data interpretation, hallucinations, and ethical considerations.
- The broader field of AI in oncology faces challenges in critical data appraisal and the need for human interaction.
Based on reviews from: Onc.ai Website, Reddit, Capterra, G2
Last updated: 2026-06-19
Videos
News, demos, and interviews about Onc.ai.
Videos load interactively. If none appear, search YouTube for Onc.ai →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Onc.ai.
Comparisons
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]